Understanding TreatmentOptions in
Cutaneous Lymphoma
36
References
37
35. WinklerCF, SausvilleEA, IhdeDC, et al.Combinedmodality treatment
of cutaneousT cell lymphoma: results of a 6-year follow-up.
JClinOncol
.
1986;4(7):1094-1100.
36. DeSimone JA,GuenovaE,Carter JB, et al.Low-dose high-dose-rate
brachytherapy in the treatment of facial lesions of cutaneousT-cell
lymphoma.
JAmAcadDermatol
. 2013;69(1):61-65.
37. DummerR,Eichmuller S,GellrichS, et al.Phase II clinical trial of
intratumoral application ofTG1042 (adenovirus-interferon-gamma) in
patientswith advanced cutaneousT-cell lymphomas andmultilesional
cutaneous B-cell lymphomas.
MolTher
. 2010;18(6):1244-1247.
38. KaplanEH,RosenST,NorrisDB,RoenigkHH, Jr., Saks SR,BunnPA, Jr.
Phase II study of recombinant human interferon gamma for treatment of
cutaneousT-cell lymphoma.
JNatlCancer Inst
. 1990;82(3):208-212.
39. ThurskyKA,WorthLJ, Seymour JF,Miles PrinceH, SlavinMA. Spectrum
of infection, risk and recommendations for prophylaxis and screening among
patientswith lymphoproliferative disorders treatedwith alemtuzumab*.
Br J
Haematol
. 2006;132(1):3-12.
40. Zinzani PL,Corradini P,Gallamini A, et al.Overview of alemtuzumab
therapy for the treatment ofT-cell lymphomas.
LeukLymphoma
.
2012;53(5):789-795.
41. BernengoMG,QuaglinoP,Comessatti A, et al.Low-dose intermittent
alemtuzumab in the treatment of Sezary syndrome: clinical and
immunologic findings in 14 patients.
Haematologica
. 2007;92(6):784-794.
42. ClarkRA,WatanabeR,Teague JE, et al. Skin effectormemoryT cells do
not recirculate andprovide immune protection in alemtuzumab-treated
CTCLpatients.
SciTranslMed
. 2012;4(117):117ra117.
43. QuerfeldC,MehtaN,RosenST, et al.Alemtuzumab for relapsed and
refractory erythrodermic cutaneousT-cell lymphoma: a single institution
experience from theRobertH.LurieComprehensiveCancerCenter.
Leuk
Lymphoma
. 2009;50(12):1969-1976.
44. Subramaniam JM,WhitesideG,McKeageK,Croxtall JC.
Mogamulizumab: first global approval.
Drugs
. 2012;72(9):1293-1298.
45. KaminetzkyD,HymesKB.Denileukindiftitox for the treatment of
cutaneousT-cell lymphoma.
Biologics
. 2008;2(4):717-724.
46. OlsenE,DuvicM, Frankel A, et al.Pivotal phase III trial of twodose levels
of denileukindiftitox for the treatment of cutaneousT-cell lymphoma.
JClinOncol
. 2001;19(2):376-388.
47. MannBS, Johnson JR,CohenMH, JusticeR,PazdurR. FDA approval
summary: vorinostat for treatment of advancedprimary cutaneousT-cell
lymphoma.
Oncologist
. 2007;12(10):1247-1252.
48. MannBS, Johnson JR,HeK, et al.Vorinostat for treatment of cutaneous
manifestations of advancedprimary cutaneousT-cell lymphoma.
Clin
CancerRes
. 2007;13(8):2318-2322.
49. PiekarzRL, FryeR,TurnerM, et al.Phase IImulti-institutional trial of the
histone deacetylase inhibitor romidepsin asmonotherapy for patientswith
cutaneousT-cell lymphoma.
JClinOncol
. 2009;27(32):5410-5417.
50. USFood andDrugAdministration. FDAApprovesDrugTreatment
forRareCancer.CutaneousT-cell lymphoma affects about 1,500
Americans annually. 2009.
PressAnnouncements/2009/ucm189629.htm.AccessedApril 22, 2013.
51. WollinaU,DummerR,BrockmeyerNH, et al.Multicenter study of
pegylated liposomal doxorubicin inpatientswith cutaneousT-cell
lymphoma.
Cancer
. 2003;98(5):993-1001.
52. Marchi E,Alinari L,TaniM, et al.Gemcitabine as frontline treatment
for cutaneousT-cell lymphoma: phase II study of 32 patients.
Cancer
.
2005;104(11):2437-2441.
53. AkilovOE,GeskinL.Therapeutic advances in cutaneousT-cell lymphoma.
SkinTherapyLett
. 2011;16(2):1-5.
54. deMassonA,Beylot-BarryM,Bouaziz JD, et al.Allogeneic stem cell
transplantation for advanced cutaneousT-cell lymphomas: a study from the
FrenchSociety of BoneMarrowTransplantation andFrenchStudyGroup
onCutaneousLymphomas.
Haematologica
. 2014;99(3):527-534.
55. Sokol L,NaghashpourM,GlassLF.Primary cutaneous B-cell
lymphomas: recent advances indiagnosis andmanagement.
CancerControl
.
2012;19(3):236-244.
56. KimYH,WillemzeR,PimpinelliN, et al.TNM classification system
for primary cutaneous lymphomas other thanmycosis fungoides and
Sezary syndrome: a proposal of the International Society forCutaneous
Lymphomas (ISCL) and theCutaneousLymphomaTaskForce of the
EuropeanOrganization of Research andTreatment ofCancer (EORTC).
Blood
. 2007;110(2):479-484.
57. SenffNJ,NoordijkEM,KimYH, et al.EuropeanOrganization for
Research andTreatment ofCancer and International Society forCutaneous
Lymphoma consensus recommendations for themanagement of cutaneous
B-cell lymphomas.
Blood
. 2008;112(5):1600-1609.
